Test of special immune-support cells for solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests lab-made mesenchymal stromal cells that release interferon alpha (IFNα) for people with locally advanced or metastatic solid cancers. It’s designed to see if this treatment can help when standard treatments have failed or don’t have guideline options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–75 years old, and your doctor expects you may live more than 3 months
- You have a confirmed solid tumor that has spread or is locally advanced, and it’s one where standard treatment didn’t work or isn’t available
- You’ve finished prior cancer treatment more than 4 weeks before starting this study
- Your scan shows at least one measurable tumor spot that can be followed
- Your general fitness is good enough (ECOG 0 to 2), and your organs (blood, liver, kidneys, etc.) are functioning well
- You can sign consent, and you won’t be pregnant or breastfeeding; if you can get pregnant, you’ll use birth control during and for 90 days after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.
This trial tests a combination of two cell-based therapies (SCTB41 and SCTB39-1) with or without standard cancer treatments for advanced solid tumors. The goal is to see if this approach helps slow or shrink tumors while being safe enough to use in patients.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.